

Adviesraad voor Bioveiligheid Conseil consultatif de Biosécurité

Advice of the Belgian Biosafety Advisory Council on application EFSA-GMO-RX-012 (oilseed rape T45) from Bayer CropScience under Regulation (EC) No. 1829/2003

19 March 2019
Ref. SC/1510/BAC/2019_0249

Context

Application EFSA-GMO-RX-012 was submitted by Bayer CropScience for the renewal of authorisation for the marketing of genetically modified (GM) oilseed rape T45 for food and feed uses, import and processing (excluding cultivation) within the European Union within the framework of Regulation (EC) No. 1829/2003¹.

The placing on the market of the glufosinate herbicide-tolerant oilseed rape T45 for food/feed uses, except cultivation, is currently authorised following a positive opinion of EFSA (The EFSA Journal (2008) 635, 1-22)².

The renewal application was validated by EFSA on 5 June 2018 and a formal three-month consultation period of the Member States was started, lasting until 10 September 2018, in accordance with Articles 6.4 and 18.4 of Regulation (EC) No. 1829/2003 (consultation of national Competent Authorities within the meaning of Directive 2001/18/EC designated by each Member State in the case of genetically modified organisms being part of the products).

Within the framework of this consultation, the coordinator for this dossier, on behalf of the Belgian Biosafety Advisory Council (BAC), decided not to request external experts to assess this dossier, since the previous application for this event had received a positive advice from the Biosafety Advisory Council, and no new relevant information was provided in the current application for renewal, which could modify the previous conclusions.

The opinion of the EFSA Scientific Panel on GMOs was published on 14 February 2019 (EFSA Journal 2018;16(11):5468)³, together with the responses from the EFSA GMO Panel to comments submitted by the Member States during the three-month consultation period.

The previous advice of the BAC on oilseed rape T45 (BAC_2008_727)⁴ and the published opinion of the EFSA GMO Panel form the basis of the advice of the Biosafety Advisory Council on application EFSA-GMO-RX-012 given below.

¹ Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed (OJ L 268, 18.10.2003, p.1).

² <http://www.efsa.europa.eu/en/efsajournal/pub/635>

³ <https://doi.org/10.2903/j.efsa.2019.5597>

⁴ http://www.bio-council.be/Advices/BAC_2008_727.pdf

Scientific evaluation

The data for application EFSA-GMO-RX-012 provided by the applicant at the time of submission included the annual post-market environmental monitoring (PMEM) reports from March 2009 to June 2018, two systematic literature searches covering the complete duration of the event's authorisation, an updated bioinformatic package including an analysis of the potential similarity of the newly expressed protein with known toxic or allergenic proteins, potential of newly created open reading frames within the insert or spanning the junctions with genomic DNA encoding peptides with sequence similar to known toxins or allergens, potential for horizontal gene transfer, and reports of additional studies performed by the applicant over the course of the authorisation period.

The Biosafety Advisory Council did not identify any information elements in the renewal application EFSA-GMO-RX-012 that would raise a safety concern for human or animal health or the environment.

Conclusion

Based on the whole set of data on oilseed rape T45 provided by the applicant, the opinion of EFSA and the original advice of the the BAC on oilseed rape T45, the Biosafety Advisory Council is of the opinion that in the context of its proposed uses, oilseed rape T45 is unlikely to pose any risk to human and animal health.

The Biosafety Advisory Council did not identify any risk that the import and processing of this GM oilseed rape could pose to the European environment.



Dr. Corinne Vander Wauven
President of the Belgian Biosafety Advisory Council